MYGN
Myriad Genetics, Inc.

2,114
Mkt Cap
$749.01M
Volume
760,021.00
52W High
$22.92
52W Low
$3.76
PE Ratio
-1.88
MYGN Fundamentals
Price
$8.05
Prev Close
$7.86
Open
$7.84
50D MA
$7.15
Beta
1.22
Avg. Volume
1.59M
EPS (Annual)
-$1.41
P/B
1.93
Rev/Employee
$310,222.22
Loading...
Loading...
News
all
press releases
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.
Zacks·16d ago
News Placeholder
More News
News Placeholder
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Zacks·22d ago
News Placeholder
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
Zacks·1mo ago
News Placeholder
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.
Zacks·2mo ago
News Placeholder
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.
Zacks·2mo ago
News Placeholder
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·3mo ago
News Placeholder
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
Zacks·4mo ago
News Placeholder
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
Zacks·5mo ago
News Placeholder
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
Zacks·5mo ago

Latest MYGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.